… Open label and non-placebo controlled trials on tetrabenazine and the RCT included in this
meta-analysis support the efficacy of this medication class in TD.69,98 VMAT2 inhibitors are …

… ie, eicosapentaenoic acid, EPA; docosapentaenoic acid, DPA and docosahexaenoic acid,
DHA) and omega-6 (ie, arachidonic acid, … randomized placebo controlled 16-week clinical trial …

… double-blind, randomized, placebo controlled trials [27,28,72]. Two long-term retrospective
… in a meta-analysis of 3 randomized, placebo-controlled clinical trials of EGb-761 (Gingko …

… randomized clinical trials assessing efficacy of different drug regimens in managing tardive
dyskinesia … , double-blind, placebo-controlled study. Mov Disord Off J Mov Disord Soc 30(12):…

… acids containing eicosapentaenoic acid >1 g/d showed significant improvement. A favorable
effect of omega-3 polyunsaturated fatty acids … 60 years; with tardive dyskinesia; unspecified; …

… Botulinum toxin or trihexyphenidyl can be considered for tardive dystonia and deep brain
stimulation or electroconvulsive therapy can be considered for disabling symptoms refractory to …

… Studies were eligible to be included in this review if they examined the effect of omega-3
fatty acids on violence in patients with schizophrenia. To be included, studies needed to have …

… , supplementation of the eicosapentaenoic acid (EPA) as an augmented … of placebo-controlled
trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. …

… as docosahexaenoic acid and eicosapentaenoic acid, have … of randomised clinical trials
investigating therapeutic effects … Randomised double-blind placebo-controlled trial of fish oil …

… Tardive dyskinesia (TD) is an involuntary movement disorder associated with agents that
block dopamine receptors, particularly antipsychotics. TD commonly involves the orofacial …